Results 21 to 30 of about 35,617 (253)
Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection [PDF]
International Journal of Molecular Sciences, 2021 Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin.
Victor Chien-Chia Wu +2 more
openaire +2 more sources
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk [PDF]
Diabetes Therapy, 2019 Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in ...
Anastasia Erythropoulou-Kaltsidou +2 more
openaire +2 more sources
Effects of sodium glucose co-transporter 2 inhibitors on the kidney [PDF]
Diabetes and Vascular Disease Research, 2018 Sodium–glucose cotransporter 2 inhibitors are antihyperglycaemic medications with an emerging evidence base for cardiovascular and kidney disease risk reduction. Sodium–glucose cotransporter 2 inhibitors medications lower plasma glucose by inhibiting glucose reabsorption in the proximal tubule of the kidney independent of insulin.
Natalia, de Albuquerque Rocha +4 more
openaire +2 more sources
Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +1 more source
Лечащий Врач, 2022 Impaired kidney function has a negative impact on the course of heart failure in both patients with and without diabetes mellitus. Therefore, the development and study of the effectiveness of methods for the treatment of chronic heart failure, especially
E. V. Kovalenko +2 more
doaj +1 more source
SGLT2 Inhibitors for Nephrologists
European Medical Journal Nephrology, 2022 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides.
Mufti Baleegh-ur-Raheem Mahmood +1 more
doaj +1 more source
IJU Case Reports, 2019 Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects.
Keita Izumi +4 more
doaj +1 more source
International Journal of Nephrology and Renovascular Disease, 2023 Rey Isidto,1 Romina Danguilan,2 Oscar Naidas,3 Russell Vilanueva,2 Mel-Hatra Arakama,2 Layla Marie Paraiso2 1HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2Department of Adult Nephrology, National ...
Isidto R +5 more
doaj
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor [PDF]
Korean Journal of Medicine, 2014 Correspondence to Jeong Hyun Park, M.D., Ph.D. Paik Institute for Clinical Research, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 614-735, Korea Tel: +82-51-890-6074, Fax: +82-51-892-0273, E-mail: pjhdoc@chol.com Copyrightc 2014 The Korean Association of Internal Medicine ...
Mi-kyung Kim, Jeong Hyun Park
openaire +1 more source
Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
ESC Heart Failure, 2021 Aims Sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) have been shown to have a relevant role in the prevention of hospitalizations for heart failure and improvement in the life expectancy of patients with diabetes and outpatients with chronic heart ...
Gianmarco Angelini +11 more
doaj +1 more source